Whither Harkin-Hatfield?

The biomedical-research community--joined by many members of Congress--was overwhelmingly in favor of the amendment. "The support for that bill this year was unlike anything I've seen," says Terry Lierman, president of Washington, D.C.based Capitol Associates Inc., a government-relations firm. But with health-care reform bills taken off the table, at least for the remainder of the year, there is no guarantee that the proposal will p

Written byBarbara Spector
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The biomedical-research community--joined by many members of Congress--was overwhelmingly in favor of the amendment. "The support for that bill this year was unlike anything I've seen," says Terry Lierman, president of Washington, D.C.based Capitol Associates Inc., a government-relations firm. But with health-care reform bills taken off the table, at least for the remainder of the year, there is no guarantee that the proposal will pass.

Harkin and Hatfield both are considered friends of biomedical research. As chairman of the Senate Appropriations Committee Subcommittee on Labor, Health and Human Services, and Education, Harkin obtained an increase in the NIH budget from $7.89 billion in 1989 (when he took over the subcommittee chairmanship) to $11.34 billion in fiscal year 1995.

Hatfield, the ranking Republican on the Appropriations Committee, was instrumental along with Harkin in setting up nationwide centers for Alzheimer's research five years ago.

In addition, he wrote legislation setting up a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies